Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Biotech
Cereno's HDAC inhibitor reduces risks from PAH in phase 2 trial
Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.
James Waldron
Sep 30, 2024 9:35am
Endotronix claims FDA approval for heart failure sensor implant
Jun 25, 2024 11:44am
Chiesi buys into Gossamer's Winrevair rival
May 6, 2024 10:28am
Merck posts fresh sotatercept data ahead of FDA approval ruling
Sep 11, 2023 7:45am
Gossamer cuts loose staff, ties future to tarnished Merck rival
May 10, 2023 6:30am
Gossamer pauses CNS med enrollment, citing risk-benefit profile
Mar 17, 2023 11:16am
